The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
YSELTY (Theramex Australia Pty Ltd)
Product name
YSELTY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (175 working days)
Active ingredients
linzagolix choline
Registration type
NCE/NBE
Indication
YSELTY is indicated for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids.